| __timestamp | Opthea Limited | Sarepta Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2652041 | 49315000 |
| Thursday, January 1, 2015 | 2361587 | 75043000 |
| Friday, January 1, 2016 | 4472869 | 83749000 |
| Sunday, January 1, 2017 | 5030957 | 122682000 |
| Monday, January 1, 2018 | 4988941 | 207761000 |
| Tuesday, January 1, 2019 | 5196412 | 284812000 |
| Wednesday, January 1, 2020 | 6652774 | 317875000 |
| Friday, January 1, 2021 | 18418247 | 282660000 |
| Saturday, January 1, 2022 | 24827066 | 451421000 |
| Sunday, January 1, 2023 | 41896408 | 481871000 |
| Monday, January 1, 2024 | 15488619 |
Infusing magic into the data realm
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Over the past decade, Sarepta Therapeutics, Inc. and Opthea Limited have taken different paths in this regard. From 2014 to 2023, Sarepta's SG&A expenses surged by over 870%, peaking at nearly half a billion dollars in 2023. In contrast, Opthea's expenses grew by approximately 1,480%, reaching a high of $41.9 million in the same year. While Sarepta's larger scale justifies higher costs, Opthea's leaner approach highlights its efficiency. Notably, 2024 data for Sarepta is missing, leaving room for speculation on future trends. Investors and analysts should consider these dynamics when evaluating the operational efficiency and strategic priorities of these companies.
Cost Management Insights: SG&A Expenses for AbbVie Inc. and Sarepta Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Gilead Sciences, Inc. and Sarepta Therapeutics, Inc.
Neurocrine Biosciences, Inc. vs Sarepta Therapeutics, Inc.: SG&A Expense Trends
Neurocrine Biosciences, Inc. and Opthea Limited: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Sarepta Therapeutics, Inc. and Exelixis, Inc.
Operational Costs Compared: SG&A Analysis of Sarepta Therapeutics, Inc. and Alkermes plc
Cost Management Insights: SG&A Expenses for Sarepta Therapeutics, Inc. and Ionis Pharmaceuticals, Inc.
Comparing SG&A Expenses: Sarepta Therapeutics, Inc. vs Wave Life Sciences Ltd. Trends and Insights
Selling, General, and Administrative Costs: Alkermes plc vs Opthea Limited
Who Optimizes SG&A Costs Better? Opthea Limited or Perrigo Company plc
SG&A Efficiency Analysis: Comparing Opthea Limited and BioCryst Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Opthea Limited and MiMedx Group, Inc.